SCR-LIP-000670 · Claim · machine-readable JSON →
No clinical study has evaluated gestrinone in lipedema, so its use as a lipedema treatment lacks direct clinical evidence.
General proposition consolidated from 2 earlier single-paper claims; each study's own result is shown as its finding.
Claim at a glance
- Type
- therapeutic
- Knowledge state
- Evidence gap
- Evidence certainty
- high (GRADE)
- Evidence
- 3 source(s) · by Amato
- Answers
- 1 question(s)
- Dates
- 2026-11-20 → 2026-11-20
Structured evidence, machine-compiled — not a verdict.
Evidence over time
Evidence (3)
- Lack of Scientific Evidence for the Use of Gestrinone in the Treatment of Lipedema: A Systematic Review — Amato et al. (2025) ✓ verified — consistent · systematic review · 2025 · risk of bias: low · reading confidence: high
“0 estudos elegíveis incluídos”
PRISMA systematic review found zero eligible trials, observational studies or case reports of gestrinone (including subcutaneous implants) for lipedema; SBEM and the Brazilian Lipedema Association oppose its use.
zero eligible studies; SBEM and Brazilian Lipedema Association oppose use - Gestrinone, lipedema, and the limits of theoretical extrapolation in clinical practice: a critical narrative review (2026) ✓ verified — consistent · review · 2026 · reading confidence: high
“No clinical trials, observational studies, case series, or case reports directly evaluating this therapy were identified. Existing proposals rely exclusively on theoretical extrapolations lacking clinical validation. Therefore, current evidence does not support the use of gestrinone in the treatment”
Critical narrative review identified no clinical trials, observational studies, case series or case reports; proposals rely only on theoretical extrapolation, and current evidence does not support gestrinone for lipedema.
The review explicitly concludes that no direct clinical evidence exists and current evidence does NOT support gestrinone for lipedema, directly contradicting the affirmative answer that it is an effective treatment. - Treatment Strategies for Lipedema: A Scoping Review on liposuction, compression therapy, bariatric surgery and pharmacological treatment (2026) ✓ verified — consistent · review · 2026 · reading confidence: high
“TRATAMENTO FARMACOLÓGICO (0 estudos elegíveis): NENHUMA evidência primária dentro do escopo da busca.”
Scoping review of lipedema treatments found zero eligible pharmacological studies; gestrinone was not among the evaluated or proposed drug therapies.
The review found no eligible pharmacological studies and does not mention gestrinone at all; proposed drugs were deemed insufficient, providing no affirmative evidence for gestrinone efficacy.
Context (PECO)
Answers these questions
Gaps & caveats
Change log
- 2026-11-20 — created_by_consolidation · general proposition consolidated from SQ-LIP-000016